Shipments of Spectamine were interrupted at a most inopportunetime. Just as clinical demand for single-photon emission computedtomography brain agents was beginning to pick up, supplier IMPhas been forced to seek financial and manufacturing partners
Shipments of Spectamine were interrupted at a most inopportunetime. Just as clinical demand for single-photon emission computedtomography brain agents was beginning to pick up, supplier IMPhas been forced to seek financial and manufacturing partners toresurrect Spectamine. Contract production of the agent was shutdown by Medi-Physics this year after IMP of Schaumburg, IL, couldn'tpay the bills (SCAN 6/17/92).
Iodine-labeled Spectamine is one of only two SPECT brain radiopharmaceuticalsapproved by the Food and Drug Administration. The other, technetium-taggedCeretec, is manufactured by Medi-Physics' parent Amersham. A secondtechnetium brain agent, Du Pont's Neurolite, will likely be thenext agent to hit the U.S. market.
Although neurological multidetector SPECT cameras have beenaround for seven or eight years, most SPECT imaging activity hasbeen on the cardiac side. Demand for brain SPECT cameras has beenincreasing of late, however, as clinical experience with the agentsgrows.
"The first three-head camera was shown in 1985. Now, in1992, people are actually buying the three-head. They are buyingit for the promise of neurology," said James L. Besett, generalmanager of Picker International's nuclear medicine division.
Developments of neurological therapies are also stimulatingthe brain SPECT market, said IMP president James F. Lamb. Therapeuticagents for stroke and Alzheimer's disease, for instance, are inclinical trials. The nuclear medicine market will benefit fromthe need to monitor and evaluate these therapies, he said.
Other forces driving the market are advances in psychiatry,where drugs are already approved, and increased use of brain SPECTin trauma applications, Lamb said.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.